Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cue Biopharma (CUE) reported a third-quarter 2026 net loss of $50.016 million while advancing its allergy and autoimmune drug programs. Revenue fell to $132,000 from $2.149 million a year earlier; net loss widened from $7.448 million. Research and development expenses rose to $17.015 million, and general and administrative expenses reached $29.826 million, including non-cash equity compensation. Cash and cash equivalents totaled $57.939 million at September 30, 2026.
In a prespecified high-IgE subgroup of the CUE-221 Phase 2 chronic spontaneous urticaria study, 78% receiving 4 mg/kg achieved complete hive resolution at week 12 versus 0% with placebo. The FDA cleared its food allergy investigational application. First-in-human dosing began for CUE-401. A November amendment increased Cue's right to receive ImmunoScape payments to $5.5 million from $5.0 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointCUE-221 Phase 2 achieved statistically significant primary and key secondary endpoints for complete hive resolution and complete response.
- Moderate pointCUE-221 food allergy investigational application received FDA clearance, enabling clinical development.
- Moderate pointCUE-401 first-in-human Phase 1 trial began, with first-cohort dosing underway.
- Moderate pointCash and cash equivalents increased to $57.939 million at September 30, 2026, from $27.136 million at December 31, 2025.
- Minor pointCUE-221 high-IgE subgroup: 78% versus 0% placebo achieved complete hive resolution at week 12 with 4 mg/kg (P < 0.005).
8 minor points
- Minor pointCUE-221 high-IgE post-hoc analysis showed 67% complete response versus 0% placebo (p < 0.05).
- Minor pointCUE-221 4 mg/kg hive-resolution benefit persisted at week 28, exceeding XOLAIR in a post-hoc analysis.
- Minor pointCUE-221 4 mg/kg suppressed free IgE below quantification in >90% at week 1, including high-baseline-IgE patients.
- Minor pointCUE-221 Phase 1 and Phase 2 studies showed well-tolerated safety profiles up to 10 mg/kg; no neutralizing antibodies observed.
- Minor point. Forward-looking: it has not happened yet and may not happen.Cue plans half-life extension efforts for CUE-221 aimed at improving patient convenience.
- Minor point. Forward-looking: it has not happened yet and may not happen.ImmunoScape payment entitlement increased to $5.5 million from $5.0 million, payable across 2026 and 2027.
- Minor pointNine-month collaboration revenue rose to $13.695 million from $5.524 million a year earlier.
- Minor pointThird-quarter interest expense declined to $2,000 from $75,000; interest income increased to $483,000 from $222,000.
Negative
- Major pointNine-month net loss widened to $208.261 million from $28.187 million; loss per share increased to $28.70 from $9.37.
- Moderate pointThird-quarter collaboration revenue fell to $132,000 from $2.149 million a year earlier.
- Minor pointThird-quarter net loss widened to $50.016 million from $7.448 million; loss per share increased to $4.74 from $2.22.
- Minor pointThird-quarter research and development expenses rose to $17.015 million from $4.754 million a year earlier.
- Minor pointThird-quarter general and administrative expenses increased to $29.826 million from $4.939 million, primarily reflecting non-cash equity compensation.
5 minor points
- Minor pointThird-quarter financial-instrument fair-value changes produced a $3.4 million loss, primarily from the contingent Ascendant top-up share obligation.
- Minor pointNine-month warrant issuance and related issuance costs generated a $90.011 million loss.
- Minor pointLiabilities increased to $28.857 million at September 30, 2026, from $15.780 million at December 31, 2025.
- Minor pointCUE-221 median free IgE rebounded to 26% of baseline at the first four-week dosing interval's end.
- Minor pointCUE-221 subcutaneous bioavailability was approximately 50% compared with intravenous administration.
News Explained
The amended five-point-five-million-dollar ImmunoScape right is payable in installments from the fourth quarter of 2026 through the fourth quarter of 2027.
Other expense included a noncash loss from revaluing a top-up share obligation: Cue Biopharma may have to issue shares to Ascendant if specified license milestones are achieved.
If issued, those additional shares would increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.
Separately, the November 2026 amendment schedules
Key Figures
- Complete hive resolution
- 78% vs. 0% with placebo
- High-baseline-IgE subgroup, 4 mg/kg at week 12; P < 0.005
- Complete response
- 67% vs. 0% with placebo
- Post-hoc analysis; p < 0.05
- Free IgE suppression
- >90% of the overall population
- Levels below the limit of quantification at the first post-dose assessment at week 1
- Revenue
- $0.1 million vs. $2.1 million
- Third quarter 2026 vs. third quarter 2025
- Research and development expenses
- $17.0 million vs. $4.8 million
- Third quarter 2026 vs. third quarter 2025
- General and administrative expenses
- $29.8 million vs. $4.9 million
- Third quarter 2026 vs. third quarter 2025
- Net loss
- $50.0 million vs. $7.4 million
- Third quarter 2026 vs. third quarter 2025
Previous Earnings Reports
-
Net loss rose sharply amid higher operating expenses, despite revenue growth and a completed private placement.
-
Clinical response results and an ImmunoScape collaboration accompanied the quarterly financial update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
chronic spontaneous urticaria medical
investigational new drug regulatory
bioavailability medical
subcutaneous medical
intravenous medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy
- CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone
- Operating results reflect expenditures related to initiation of clinical development program expenses and non-cash charges
BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.
“We are seeing exciting momentum across our portfolio,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy. The additional clinical and pharmacological findings shared today from our Phase 2 CSU study reinforce CUE-221’s differentiated profile in CSU and provide a strong foundation to advance our food allergy program. In addition, commencement of dosing in our CUE-401 Phase 1 trial marks a significant milestone for Cue Biopharma as our first autoimmune therapeutic candidate enters the clinic.”
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience,” said Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma. “CUE-401 is a potentially first-in-class dual-agonist, precision engineered by Cue scientists and designed to unlock the potential of TGF-β biology and restore immune tolerance. We believe this differentiated approach offers broad opportunities to address high unmet needs across autoimmune diseases. We look forward to sharing further progress as we advance our portfolio of therapies aimed at delivering durable, disease-modifying benefits across allergic and autoimmune diseases.”
Business Highlights
CUE-221: Phase 2 CSU Study Results
We announced positive Phase 2 CSU topline results demonstrating highly statistically significant dose responsive clinical impact on the primary endpoint of complete hives resolution (HSS7=0) and statistically significant improvement on the key secondary endpoint of complete response (UAS7=0).
Previously reported durable clinical benefit (HSS7=0) at week 28 (12 weeks after the last dose) in the 4mg/kg dose group persisted in the absence of clinically meaningful drug exposure, was not observed at lower doses, and was significantly greater than XOLAIR® (omalizumab) in a post-hoc analysis, implicating biological effects beyond IgE neutralization alone. These findings are consistent with CUE-221’s dual mechanism of action designed to both neutralize IgE and prevent the synthesis of new IgE.
The study enrolled patients across a broad range of baseline IgE (median of 427 ng/mL [178 IU/m], range up to 7860, ng/mL, with approximately one-third having high IgE ≥ 720 ng/mL (300 IU/mL).
In the study, CUE-221 demonstrated rapid, profound and dose-responsive free IgE suppression. At 4 mg/kg, all patients in the intensive PK subgroup achieved levels below the limit of quantification within hours of dosing with >
In a prespecified subgroup analysis of patients with high baseline IgE ≥ 300 IU/mL,
Collectively, the Phase 1 and Phase 2 CSU studies of CUE-221 demonstrated favorable and well-tolerated safety profiles, up to 10 mg/kg. No neutralizing antibodies have been observed. The phase 2 study identified 4 mg/kg as the dose at which differentiated clinical benefit emerged relative to lower doses and XOLAIR. Bioavailability was approximately
The CUE-221 Investigational New Drug (IND) application for food allergy has been cleared by the Food and Drug Administration (FDA), enabling advancement of the clinical development program.
CUE-401 Advancing a Potentially First-in-Class Precision Engineered Dual-Agonist for Autoimmune Disease
- Initiated the first-in-human Phase 1 trial, with dosing underway in the first cohort.
- CUE-401, Cue’s lead autoimmune candidate, is designed to regulate inflammation and drive Treg-mediated tolerance.
Third Quarter 2026 Financial Results
Third quarter revenue was
Research and development expenses were
General and administrative expenses were
Other income and expense for the three months ended September 30, 2026, primarily comprised a net non-cash loss related to the revaluation of the top-up share obligation for shares the Company may be required to issue to Ascendant under the license agreement upon the achievement of certain milestones.
Net loss for the three months ended September 30, 2026, was
As of September 30, 2026, the Company had
| Cue Biopharma, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited; In thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Collaboration revenue | $ | 132 | $ | 2,149 | $ | 13,695 | $ | 5,524 | ||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | 29,826 | 4,939 | 80,543 | 12,792 | ||||||||||||
| Research and development | 17,015 | 4,754 | 72,919 | 21,211 | ||||||||||||
| Loss on fixed asset disposal | — | 51 | — | 51 | ||||||||||||
| Gain on lease termination | (110 | ) | — | (120 | ) | — | ||||||||||
| Loss on write-off of lease security deposit | 498 | — | 498 | — | ||||||||||||
| Total operating expenses | 47,229 | 9,744 | 153,840 | 34,054 | ||||||||||||
| Loss from operations | (47,097 | ) | (7,595 | ) | (140,145 | ) | (28,530 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 483 | 222 | 819 | 649 | ||||||||||||
| Interest expense | (2 | ) | (75 | ) | (11 | ) | (306 | ) | ||||||||
| Loss on issuance of liability-classified warrants and related issuance costs | — | — | (90,011 | ) | — | |||||||||||
| Changes in fair value of financial instruments | (3,400 | ) | — | 21,087 | — | |||||||||||
| Total other income (expense), net | (2,919 | ) | 147 | (68,116 | ) | 343 | ||||||||||
| Net loss | $ | (50,016 | ) | $ | (7,448 | ) | $ | (208,261 | ) | $ | (28,187 | ) | ||||
| Unrealized gain from available-for-sale securities | — | 1 | — | 1 | ||||||||||||
| Comprehensive loss | $ | (50,016 | ) | $ | (7,447 | ) | $ | (208,261 | ) | $ | (28,186 | ) | ||||
| Net loss per common share – basic and diluted | $ | (4.74 | ) | $ | (2.22 | ) | $ | (28.70 | ) | $ | (9.37 | ) | ||||
| Weighted average common shares outstanding – basic and diluted | 10,561,814 | 3,362,311 | 7,255,392 | 3,009,035 | ||||||||||||
| Cue Biopharma, Inc. Condensed Consolidated Balance Sheets (Unaudited, In thousands) | ||||||
| September 30, 2026 | December 31, 2025 | |||||
| Assets | ||||||
| Cash and cash equivalents | $ | 57,939 | $ | 27,136 | ||
| Other assets | 9,316 | 15,076 | ||||
| Total assets | $ | 67,255 | $ | 42,212 | ||
| Liabilities and stockholders’ equity | ||||||
| Liabilities | $ | 28,857 | $ | 15,780 | ||
| Stockholders' equity | 38,398 | 26,432 | ||||
| Total liabilities and stockholders’ equity | $ | 67,255 | $ | 42,212 | ||
About CUE-221
CUE-221 (Ascendant-221, UB-221) is a humanized anti-IgE IgG1 monoclonal antibody designed with a precision engineered dual mechanism of action. CUE-221 binds to IgE at sites that are distinct from the binding sites for XOLAIR® or other similar anti-IgE monoclonal antibodies. In doing so, it maintains the capacity of total IgE to bind the CD23 receptor at the surface of B cells, resulting in reduced IgE synthesis. Therefore, CUE-221 is a functionally distinct novel anti-IgE antibody designed to not only neutralize free IgE with high potency, but also to prevent the synthesis of new IgE with the possibility to achieve b-cell quiescence through crosslinking of CD23 which could ultimately result in sustained disease control beyond drug exposure. The CUE-221 Phase 2 clinical trial in CSU produced positive topline results and clinical evidence providing initial validation of the clinical potential of a precision engineered anti-IgE dual mechanism of action. The study also demonstrated fundamental biological differences compared to XOLAIR®.
About CUE-401
CUE-401 is a bispecific fusion protein of 2 human cytokines: IL-2 and TGFβ, each engineered in an attenuated form so as to decrease their affinity for their respective cognate receptor to limit the potential for broader off-target or adverse immunomodulatory effects. The design of CUE-401 stemmed from the Nobel Prize winning discovery of the role of regulatory T cells (Tregs) in autoimmunity, granted in 2025, and the recognition that the cytokines IL-2 and TGF-beta, when acting in concert are essential components in establishing immune tolerance by fostering the development of Tregs.
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at delivering durable, potentially disease-modifying benefits across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is currently the subject of a Phase 1 clinical trial and is designed to regulate inflammation and drive Treg-mediated tolerance.
Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates. For more information, please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including its potential benefits to patients suffering from allergic and autoimmune diseases; the company’s plans to further advance its differentiating Immuno-STAT platform and its lead asset, CUE-221, and its lead autoimmune candidate, CUE-401, including expected timing of clinical trial initiation and data readout; the expected benefits from the company’s license agreement with Ascendant; and expectations regarding the company’s growth, and the company’s business strategies, plans, and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “aim,” “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise,” “potential” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain and establish collaboration, licensing and other arrangements; the company’s limited operating history, limited cash and a history of losses; the company’s ability to obtain adequate financing to fund its business operations; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts for its current and future drug product candidates, including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; potential challenges associated with clinical trials conducted in China and the company’s access to, and acceptability of, the data therefrom; its ability to secure required FDA or other governmental approvals for its product candidates and the breadth of any approved indication; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Investor and Media Contacts
Agnes Lee
Chief Investor Relations & Communications Officer
alee@cuebio.com
Marie Campinell
Senior Director, Corporate Communications
ir@cuebio.com
Cue Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Cue Biopharma's third-quarter 2026 financial results?
Cue Biopharma reported $132,000 in revenue and a $50.016 million net loss for the three months ended September 30, 2026. Revenue was $2.149 million and net loss was $7.448 million in the prior-year quarter. Basic and diluted loss per share increased to $4.74 from $2.22.
What did Cue Biopharma's CUE-221 Phase 2 study show in high-IgE patients?
In a prespecified subgroup with baseline IgE of at least 300 IU/mL, 78% receiving 4 mg/kg achieved complete hive resolution at week 12 versus 0% with placebo (P < 0.005). A subsequent post-hoc analysis found complete response, measured by UAS7=0, in 67% versus 0% with placebo (p < 0.05).
When will Cue Biopharma receive the amended ImmunoScape payments?
The amended payment schedule is $3.0 million in the fourth quarter of 2026, $1.5 million in the third quarter of 2027 and $1.0 million in the fourth quarter of 2027. The November 2026 amendment increased Cue's total payment entitlement from $5.0 million to $5.5 million.